Baird analyst Brian Skorney lowered the firm’s price target on Sarepta (SRPT) to $20 from $22 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results.
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta downside risks outweigh upside potential, says Citi
- Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
- Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside
- Sarepta CEO to retire
- Sarepta Therapeutics Announces Planned CEO Leadership Transition